Alpine Biomed eyes global role with Medtronic diagnostics assets
This article was originally published in Clinica
Executive Summary
Alpine Biomed is staking out a global leadership position in the specialty diagnostics market after completing the purchase of Medtronic's neurodiagnostic product line for an undisclosed sum on August 1. The Fountain Valley, California company gained all Medtronic neurodiagnostic equipment and accessories, including the Keypoint electromyography (EMG), Clavis hand-held EMG injection device, and needle and surface electrodes. It is Alpine's second deal with Medtronic this year: in May it purchased Medtronic's gastroenterology diagnostic product line, and this latest transaction sees Alpine acquire the whole range of diagnostics tools, ready for integration into its own portfolio for the treatment of various neuropathies.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.